Breakthrough in Lupus Treatment: Fate Therapeutics Initiates First-of-its-Kind CAR-T Cell Study
In a significant advancement in the treatment of autoimmune diseases, Fate Therapeutics has announced the commencement of a pioneering clinical study targeting systemic lupus erythematosus (SLE), commonly known as lupus. This marks the first time a patient with lupus has been treated using an “off-the-shelf” chimeric antigen receptor (CAR) T-cell therapy, a groundbreaking approach that […]
Beam’s Breakthrough: Revolutionizing Genetic Medicine?
Beam Therapeutics Inc., a leading biotechnology company specializing in precision genetic medicines through base editing, has recently made a significant announcement. In August, the company initiated treatment for its first patient with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therapy. This therapy is currently under evaluation in a Phase 1/2 clinical trial aimed at treating […]